Skip to content
Medical Health Aged Care, National News Current Affairs

New discovery for treatment of primary liver cancer

Monash University 2 mins read

A preclinical study led by Monash University has discovered a drug combination with the potential to treat one of the most fatal and globally widespread cancers, a type of primary liver cancer called hepatocellular carcinoma (HCC).

The team of researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) found the drug combination reverses the symptoms of nonalcoholic steatohepatitis (NASH) and, subsequently, markedly reduces the onset of NASH-driven HCC, without affecting the liver in mice.

The study, published in Science Advances, used a mouse model that mimics human NASH-driven HCC to implement a combination treatment of an endoplasmic reticulum (ER) stress inhibitor called ‘BGP-15’ with the inflammation blocker, ‘Olamkicept’. 

Both of these drugs are already proven to be safe in humans and have progressed to Phase 2 and 3 human clinical trials for other metabolic and/or inflammatory diseases. 

The study’s lead author, Professor Mark Febbraio from MIPS, said this is an exciting discovery for a particularly widespread and devastating disease with a low survival rate.

“HCC is increasing at an alarming rate largely due to increased obesity and type 2 diabetes which may lead to NASH, a well known HCC risk factor,” said Professor Febbraio. 

The rise in HCC coincides with patients presenting with obesity and symptoms associated with the metabolic syndrome, especially metabolic dysfunction-associated fatty liver disease (MAFLD). Globally, a staggering 25 per cent of the population are estimated to be living with MAFLD, with around 15 per cent of those exhibiting signs of NASH.

“Despite the high prevalence of NASH and the alarming rise in NASH-driven HCC, there are currently no FDA approved treatments that halt disease progression.

“Given that ER stress and inflammation are hallmarks of NASH-driven HCC, and that BGP-15 and Olamkicept have both already proven to be safe, we tested whether these drugs – as monotherapy, or in combination – would prevent NASH and/or NASH driven HCC in mice.

“Consistent with our hypothesis, the study shows that while monotherapy with either of the two drugs modestly slowed progression, when combined they have shown to be a realistic therapeutic strategy for treating human NASH and progression to HCC, diseases that are rapidly growing with a clinical unmet need.”

Professor Febbraio said that given the significance of the discovery, combined with the urgent need for new safe and effective treatments for NASH and NASH-driven HCC, the team ultimately hope their findings will progress toward clinical trials. 

“We have to stress that this study was performed in mice, not humans. However, as both drugs have been shown to be safe in several human clinical trials, the logical next step is testing the BGP-15/Olamkicept combination in clinical trials for patients with NASH and or HCC.”

https://www.science.org/doi/full/10.1126/sciadv.adh0831?af=R


Contact details:

Kate Carthew - Media and Communications Manager
E: [email protected]
T: +61 (0) 438 674 814

Media

More from this category

  • Medical Health Aged Care
  • 10/07/2025
  • 09:00
Monash University

Australians join elite group of scientists using AI to create man-made proteins

For the first time, Australian scientists have used Artificial Intelligence (AI) to generate a ready-to-use biological protein, in this case, one that can kill antibiotic resistant bacteria like E. coli. There has been a recent surge in proteins developed by AI that will eventually be used in the treatment of everything from snakebites to cancer. What would normally take decades for a scientist to create – a custom-made protein for a particular disease – can now be done in seconds. This study, published in Nature Communications, provides a new way to combat the growing crisis caused by antibiotic resistant super…

  • Indigenous, Medical Health Aged Care
  • 10/07/2025
  • 08:01
Monash University

Monash expert: Improving bone health in First Nations communities

AsNAIDOC Week continues, a Monash University studypublished in the MJA has found that increasing bone health awareness across Indigenous communities by a Community-led, co-created education program was valued as it would be beneficial for Indigenous people across the life course. “To be effective, incorporating traditional Indigenous ways and knowledge along with present‐day health evidence is required,” the researchers found. Available to comment: Dr Troy Walker, who did this work with theMonash School of Clinical Sciences at Monash Health, Department of MedicineContact: +61 3 9903 4840 or [email protected] Musculoskeletal health, strength and conditioning, Aboriginal health Diet, nutrition, lifestyle medicine Clinical pain…

  • National News Current Affairs, Youth
  • 10/07/2025
  • 07:18
Act for Kids

Modern sex education must address AI risks

The growing risks associated with artificial intelligence must be incorporated into age-appropriate sex education talks with kids, a leading child protection organisation has warned. Act for Kids says parents, carers, schools and educators need to be informed and prepared, with generative AI emerging as a strong trend in online child abuse and exploitation and sextortion material. The warning follows a spate of serious incidents involving Australian school students using AI technology to generate illegal child abuse material inappropriately depicting classmates and peers. In 2024, the National Centre for Missing and Exploited Children (NCMEC) flagged a staggering 1325 per cent rise…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.